Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21519517 | 0.78 | DNM1 (0.38) | DNM1CNR2 | |
| SCHEMBL5715845 | 0.77 | SOAT1 (0.39) | PPARGPPARAPPARDSOAT1CNR2 | |
| SCHEMBL5082545 | 0.75 | DNM1 (0.42) | DNM1THRBCNR2 | |
| SCHEMBL21519592 | 0.75 | DNM1 (0.42) | DNM1THRBCNR2 | |
| SCHEMBL5088802 | 0.75 | DNM1 (0.42) | DNM1THRBCNR2 | |
| SCHEMBL29002046 | 0.75 | DNM1 (0.42) | DNM1THRBCNR2 | |
| SCHEMBL3978473 | 0.75 | DNM1 (0.42) | DNM1THRBCNR2 | |
| SCHEMBL5715939 | 0.74 | CNR2 (0.40) | PPARGPPARAPPARDSOAT1CNR2 | |
| SCHEMBL5716608 | 0.74 | DNM1 (0.41) | DNM1THRB | |
| Hydrochloric Acid SCHEMBL29002048 | 0.74 | DNM1 (0.44) | DNM1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299405-B1 | POLYCYCLIC, FUSED RING COMPOUNDS, METAL COMPLEXES AND POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES INC (US) | 2009-05-13 | — | — | EP | claimed |
| US-6800701-B2 | USING COORDINATION CATALYSTS | DOW GLOBAL TECHNOLOGIES INC. | 2004-10-05 | — | — | US | claimed |
| US-20030216529-A1 | Polycyclic, fused ring compounds, metal complexes and polymerization process | DOW GLOBAL TECHNOLOGIES LLC | 2003-11-20 | — | — | US | claimed |
| EP-1299405-A1 | POLYCYCLIC, FUSED RING COMPOUNDS, METAL COMPLEXES AND POLYMERIZATION PROCESS | THE DOW CHEMICAL COMPANY (US) | 2003-04-09 | — | — | EP | claimed |
| US-20020062011-A1 | Polycyclic, fused ring compounds, metal complexes and polymerization process | DOW GLOBAL TECHNOLOGIES LLC | 2002-05-23 | — | — | US | claimed |
| WO-2002002577-A1 | POLYCYCLIC, FUSED RING COMPOUNDS, METAL COMPLEXES AND POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGY INC. (US) | 2002-01-10 | — | — | WO | claimed |
| EP-1299405-B1 | POLYCYCLIC, FUSED RING COMPOUNDS, METAL COMPLEXES AND POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES INC (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-1487886-B1 | SUBSTITUTED INDENYL METAL COMPLEXES AND POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080051531-A1 | GAS PHASE PROCESS FOR POLYMERS WITH GROUP 4 METAL COMPLEX CATALYST ADDITION | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| EP-1497301-B1 | SUBSTITUTED POLYCYCLIC, FUSED RING METAL COMPLEXES AND POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES INC (US) | 2006-11-29 | — | — | EP | disclosed |
| US-6984602-B2 | Olefin polymerization catalysts containing a pyrrole bisimine ligand | UNIVATION TECHNOLOGIES, LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-6946531-B2 | Low molecular weight ethylene interpolymers and polymerization process | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-6943133-B2 | Diene functionalized catalyst supports and supported catalyst compositions | UNIVATION TECHNOLOGIES, LLC (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2002074779-A1 | METAL COMPLEXES CONTAINING ACETYLENIC LIGANDS, POLYMERIZATION CATALYSTS AND ADDITION POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| US-20020082161-A1 | Diene functionalized catalyst supports and supported catalyst compositions | THE DOW CHEMICAL COMPANY | 2002-06-27 | — | — | US | disclosed |
| US-20020072577-A1 | Supported catalyst compositions | THE DOW CHEMICAL COMPANY | 2002-06-13 | — | — | US | disclosed |
| US-20020062011-A1 | Polycyclic, fused ring compounds, metal complexes and polymerization process | DOW GLOBAL TECHNOLOGIES LLC | 2002-05-23 | — | — | US | disclosed |
| WO-2002028921-A1 | SUPPORTED CATALYST COMPOSITIONS | THE DOW CHEMICAL COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
| WO-2002002577-A1 | POLYCYCLIC, FUSED RING COMPOUNDS, METAL COMPLEXES AND POLYMERIZATION PROCESS | DOW GLOBAL TECHNOLOGY INC. (US) | 2002-01-10 | — | — | WO | disclosed |
| US-20010025115-A1 | Bridged metal complexes | DOW GLOBAL TECHNOLOGIES LLC | 2001-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025115-A1 | Bridged metal complexes | SLC39A14, NBAS, MCM4 | DNM1 967/4885PPARG 3888/4885PPARA 4287/4885 |
| US-20030216529-A1 | Polycyclic, fused ring compounds, metal complexes and polymerization process | PIN1, ZC3H18, ORC3 | DNM1 187/4885PPARG 3228/4885PPARA 2141/4885 |
| US-20020062011-A1 | Polycyclic, fused ring compounds, metal complexes and polymerization process | PIN1, ZC3H18, ORC3 | DNM1 187/4885PPARG 3228/4885PPARA 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.